Products Risankizumab was approved in the United States and in many countries in 2019 as a solution for injection (Skyrizi). Structure and properties Risankizumab is a humanized IgG1 monoclonal antibody produced by biotechnological methods. Effects Risankizumab (ATC L04AC) has selective immunosuppressive and anti-inflammatory properties. The antibody binds to the p19 subunit of human interleukin-23 (IL-23), … Risankizumab
Products Guselkumab was approved in the United States and the EU in 2017 and in many countries in 2018 as a solution for injection for subcutaneous use (Tremfya). Structure and properties Guselkumab is an IgG1λ monoclonal antibody produced by biotechnological methods. Effects Guselkumab (ATC L04AC16) has anti-inflammatory and immunosuppressive properties. The effects are due to … Guselkumab
Products Tildrakizumab was approved as an injectable in the United States and EU in 2018 and in many countries in 2019 (ilumetri). Structure and properties Tildrakizumab is a humanized IgG1/k monoclonal antibody with an approximate molecular mass of 147 kDa. It is produced by biotechnological methods. Effects Tildrakizumab (ATC L04AC17) has immunosuppressive and anti-inflammatory properties. … Tildrakizumab